Evidence map›Paper›PMID 17036377›Full record

ReviewWorld journal of gastroenterology2006

Gene therapy of liver cancer.

Ruben Hernandez-Alcoceba, Bruno Sangro, Jesus Prieto

Abstract readEditorialReview
In one paragraph

Review in World journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Gene therapy for people with hepatocellular carcinoma.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ruben Hernandez-AlcocebaDivision of Gene Therapy and Hepatology, Edificio CIMA, Av. Pio XII, 55, Pamplona 31008, Spain.
Bruno Sangro
Jesus Prieto

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The application of gene transfer technologies to the treatment of cancer has led to the development of new experimental approaches like gene directed enzyme/pro-drug therapy (GDEPT), inhibition of oncogenes and restoration of tumor-suppressor genes. In addition, gene therapy has a big impact on other fields like cancer immunotherapy, anti-angiogenic therapy and virotherapy. These strategies are being evaluated for the treatment of primary and metastatic liver cancer and some of them have reached clinical phases. We present a review on the basis and the actual status of gene therapy approaches applied to liver cancer.

Indexed as

Angiogenesis InhibitorsApoptosisCarcinoma, HepatocellularGene ExpressionGenes, Tumor SuppressorGene TargetingGenetic TherapyHumansImmunotherapyLiver NeoplasmsOncogenesOncolytic VirotherapyProdrugsAngiogenesis InhibitorsProdrugs

Identifiers

PMID17036377
PMCPMC4088099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.